Oana Ursu

Oana Ursu

Auto-generated profile, based on publicly available information

Oana Ursu

Broad Institute of Harvard and MIT, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
DMDavid W. Morgens
David W. Morgens
MWMichael Wainberg
Michael Wainberg
EBEvan A. Boyle
Evan A. Boyle
OUOana Ursu
Oana Ursu
CACarlos L. Araya
Carlos L. Araya
MBMichael C. Bassik
Michael C. Bassik
CRISPR-Cas9 screens are powerful tools for high-throughput interrogation of genome function, but can be confounded by nuclease-induced toxicity at both on- and off-target sites, likely due to DNA damage. Here, to test potential solutions to this issue, we design and analyse a CRISPR-Cas9 library with 10 variable-length guides per gene and thousands of negative controls targeting non-functional, non-genic regions (termed safe-targeting guides), in addition to non-targeting controls. We find this library has excellent performance in identifying genes affecting growth and sensitivity to the ricin toxin. The safe-targeting guides allow for proper control of toxicity from on-target DNA damage. Using this toxicity as a proxy to measure off-target cutting, we demonstrate with tens of thousands of guides both the nucleotide position-dependent sensitivity to single mismatches and the reduction of off-target cutting using truncated guides. Our results demonstrate a simple strategy for high-throughput evaluation of target specificity and nuclease toxicity in Cas9 screens.

1 August 2015 in Cell
Verified
Journal Article
Closed access
FGFabian Grubert
Fabian Grubert
JZJudith B. Zaugg
Judith B. Zaugg
MKMaya Kasowski
Maya Kasowski
OUOana Ursu
Oana Ursu
DSDamek V. Spacek
Damek V. Spacek
MSMichael P Snyder
Michael P Snyder

15 March 2018 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
OUOana Ursu
Oana Ursu
NBNathan Boley
Nathan Boley
MTMaryna Taranova
Maryna Taranova
YWY X Rachel Wang
Y X Rachel Wang
GYGalip Gurkan Yardimci
Galip Gurkan Yardimci
AKAnshul Kundaje
Anshul Kundaje
The three-dimensional organization of chromatin plays a critical role in gene regulation and disease. High-throughput chromosome conformation capture experiments such as Hi-C are used to obtain genome-wide maps of three-dimensional chromatin contacts. However, robust estimation of data quality and systematic comparison of these contact maps is challenging due to the multi-scale, hierarchical structure of chromatin contacts and the resulting properties of experimental noise in the data. Measuring concordance of contact maps is important for assessing reproducibility of replicate experiments and for modeling variation between different cellular contexts. We introduce a concordance measure called DIfferences between Smoothed COntact maps (GenomeDISCO) for assessing the similarity of a pair of contact maps obtained from chromosome conformation capture experiments. The key idea is to smooth contact maps using random walks on the contact map graph, before estimating concordance. We use simulated datasets to benchmark GenomeDISCO's sensitivity to different types of noise that affect chromatin contact maps. When applied to a large collection of Hi-C datasets, GenomeDISCO accurately distinguishes biological replicates from samples obtained from different cell types. GenomeDISCO also generalizes to other chromosome conformation capture assays, such as HiChIP. Software implementing GenomeDISCO is available at https://github.com/kundajelab/genomedisco. Supplementary data are available at Bioinformatics online.

1 January 2012 in Integrative Biology
Verified
Journal Article
Open access
PDF file
SGSara JC Gosline
Sara JC Gosline
SSSarah J. Spencer
Sarah J. Spencer
OUOana Ursu
Oana Ursu
EFErnest Fraenkel
Ernest Fraenkel
Cellular responses activate overlapping pathways, which are frequently the only ones identified by analysis of high-throughput data. Using a constrained op

17 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
OUOana Ursu
Oana Ursu
JNJames T. Neal
James T. Neal
ESEmily Shea
Emily Shea
PTPratiksha I. Thakore
Pratiksha I. Thakore
LJLivnat Jerby-Arnon
Livnat Jerby-Arnon
JBJesse S. Boehm
Jesse S. Boehm
Genome sequencing studies have identified millions of somatic variants in cancer, but their phenotypic impact remains challenging to predict. Current experimental approaches to distinguish between functionally impactful and neutral variants require customized phenotypic assays that often report on average effects, and are not easily scaled. Here, we develop a generalizable, high-dimensional, and scalable approach to functionally assess variant impact in single cells by pooled Perturb-seq. Specifically, we assessed the impact of 200 TP53 and KRAS variants in >300,000 single lung cancer cells, and used the profiles to categorize variants into phenotypic subsets to distinguish gain-of-function, loss-of-function and dominant negative variants, which we validated by comparison to orthogonal assays. Surprisingly, KRAS variants did not merely fit into discrete functional categories, but rather spanned a continuum of gain-of-function phenotypes driven by quantitative shifts in cell composition at the single cell level. We further discovered novel gain-of-function KRAS variants whose impact could not have been predicted solely by their occurrence in patient samples. Our work provides a scalable, gene-agnostic method for coding variant impact phenotyping, which can be applied in cancer and other diseases driven by somatic or germline coding mutations.

12 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OUOana Ursu
Oana Ursu
SGSara JC Gosline
Sara JC Gosline
NBNeil Beeharry
Neil Beeharry
LFLauren Fink
Lauren Fink
VBVikram Bhattacharjee
Vikram Bhattacharjee
EFErnest Fraenkel
Ernest Fraenkel
Small molecule screens are widely used to prioritize pharmaceutical development. However, determining the pathways targeted by these molecules is challenging, since the compounds are often promiscuous. We present a network strategy that takes into account the polypharmacology of small molecules in order to generate hypotheses for their broader mode of action. We report a screen for kinase inhibitors that increase the efficacy of gemcitabine, the first-line chemotherapy for pancreatic cancer. Eight kinase inhibitors emerge that are known to affect 201 kinases, of which only three kinases have been previously identified as modifiers of gemcitabine toxicity. In this work, we use the SAMNet algorithm to identify pathways linking these kinases and genetic modifiers of gemcitabine toxicity with transcriptional and epigenetic changes induced by gemcitabine that we measure using DNaseI-seq and RNA-seq. SAMNet uses a constrained optimization algorithm to connect genes from these complementary datasets through a small set of protein-protein and protein-DNA interactions. The resulting network recapitulates known pathways including DNA repair, cell proliferation and the epithelial-to-mesenchymal transition. We use the network to predict genes with important roles in the gemcitabine response, including six that have already been shown to modify gemcitabine efficacy in pancreatic cancer and ten novel candidates. Our work reveals the important role of polypharmacology in the activity of these chemosensitizing agents.